Functional PLGA NPs for oral drug delivery: recent strategies and developments.
about
Periadventitial application of rapamycin-loaded nanoparticles produces sustained inhibition of vascular restenosisQuantification of particle-conjugated or particle-encapsulated peptides on interfering reagent backgrounds.In vitro controlled release of antigen in dendritic cells using pH-sensitive liposome-polymeric hybrid nanoparticles.Glucose-Based Mesoporous Carbon Nanospheres as Functional Carriers for Oral Delivery of Amphiphobic Raloxifene: Insights into the Bioavailability Enhancement and Lymphatic Transport.Cytotoxicity and intracellular fate of PLGA and chitosan-coated PLGA nanoparticles in Madin-Darby bovine kidney (MDBK) and human colorectal adenocarcinoma (Colo 205) cells.Preparation and characterization of zwitterionic phospholipid polymer-coated poly(lactic acid) nanoparticles.Enhancement of oral bioavailability of cyclosporine A: comparison of various nanoscale drug-delivery systems.Gold nanoparticle-based miR155 antagonist macrophage delivery restores the cardiac function in ovariectomized diabetic mouse model.The binary complex of poly(PEGMA-co-MAA) hydrogel and PLGA nanoparticles as a novel oral drug delivery system for ibuprofen delivery.Design of Insulin-Loaded Nanoparticles Enabled by Multistep Control of Nanoprecipitation and Zinc Chelation.PLGA-encapsulated perfluorocarbon nanoparticles for simultaneous visualization of distinct cell populations by 19F MRI.Modification of solid lipid nanoparticles loaded with nebivolol hydrochloride for improvement of oral bioavailability in treatment of hypertension: polyethylene glycol versus chitosan oligosaccharide lactate.Drug release behavior of poly (lactic-glycolic acid) grafting from sodium alginate (ALG-g-PLGA) prepared by direct polycondensation.Accelerated wound healing by injectable star poly(ethylene glycol)-b-poly(propylene sulfide) scaffolds loaded with poorly water-soluble drugs.Nanotechnology in retinal drug delivery.
P2860
Q27321271-D8449027-6F86-4528-9D52-02F49959BF6FQ34018575-B1E52C28-D4CE-4037-8494-7871606C10F6Q36326918-9E50C592-BF53-48C8-B595-4C0BC7C2E3A1Q38820627-2A4A6F39-A09B-4CCE-9457-1870D637594DQ38874656-4BF6AA32-F7CE-4515-81D5-8031F048949BQ38960278-74CFAF49-F117-442C-8209-358078E30A12Q39574444-29EE1D5C-12F8-420F-B180-B796B0A73289Q41037110-4F6D4265-29F0-4A4A-BF48-F1B48B81038BQ47940771-B7064E50-393B-45AD-8367-7EBCE994FE58Q48097918-B9993E03-9EE0-457B-904A-B596B1011691Q48657577-E3A264B3-3CE8-4F33-8175-15E5FDBDE9DEQ50927252-1E92BD00-28CE-4B09-8152-7C84C900AE67Q51816692-038A4C7B-FA42-4B82-B254-2282982FBA04Q54979276-14AF1679-735D-4556-B6AB-2B116DFB62C3Q55491207-BF0BB60D-06CE-4E07-BA2C-29B2421206C6
P2860
Functional PLGA NPs for oral drug delivery: recent strategies and developments.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Functional PLGA NPs for oral drug delivery: recent strategies and developments.
@en
type
label
Functional PLGA NPs for oral drug delivery: recent strategies and developments.
@en
prefLabel
Functional PLGA NPs for oral drug delivery: recent strategies and developments.
@en
P2093
P1476
Functional PLGA NPs for oral drug delivery: recent strategies and developments
@en
P2093
I Muñoz-Rubio
J Alvarez-Fuentes
L Martin-Banderas
M A Holgado
M Durán-Lobato
P356
10.2174/138955713804484721
P577
2013-01-01T00:00:00Z